2025/11/27 更新

写真a

ミヤケ ヒロマサ
三宅 広将
所属
医歯薬学域 助教
職名
助教
外部リンク

学位

  • 博士(医学) ( 2021年3月   岡山大学 )

  • 学士(医学) ( 2017年3月   岡山大学 )

研究キーワード

  • 代謝機能障害関連脂肪性肝疾患(MASLD)

  • メタボリックシンドローム

  • 代謝機能障害関連脂肪肝炎(MASH)

  • 糖尿病性腎臓病

  • ポドサイドパチー

  • 糖尿病性腎症

学歴

  • 岡山大学大学院医歯薬学総合研究科   腎・免疫・内分泌代謝内科学  

    2017年4月 - 2021年3月

      詳細を見る

  • 岡山大学   Medical School   Faculty of Medicine

    2011年4月 - 2017年3月

      詳細を見る

経歴

  • 岡山大学大学院医歯薬学総合研究科   腎・免疫・内分泌代謝内科学   客員研究員

    2025年7月 - 現在

      詳細を見る

    国名:日本国

    researchmap

  • 岡山大学   病態生理・創薬学   非常勤研究員

    2025年4月 - 2025年6月

      詳細を見る

    国名:日本国

    researchmap

  • 岡山大学大学院医歯薬学総合研究科   腎・免疫・内分泌代謝内科学   客員研究員

    2024年4月 - 2025年3月

      詳細を見る

  • 岡山大学病院   腎臓・糖尿病・内分泌内科   医員

    2023年4月 - 2024年3月

      詳細を見る

  • 広島市立広島市民病院   腎臓内科   医員

    2022年4月 - 2023年3月

      詳細を見る

  • 広島市立舟入市民病院   内科   医員

    2021年10月 - 2022年3月

      詳細を見る

  • JR広島病院   内科   医員

    2021年4月 - 2021年9月

      詳細を見る

  • 広島市立広島市民病院   腎臓内科   医員

    2019年4月 - 2021年3月

      詳細を見る

  • 岡山大学病院   研修医

    2017年4月 - 2019年3月

      詳細を見る

▼全件表示

所属学協会

  • 日本内科学会

    2019年4月 - 現在

      詳細を見る

  • 日本腎臓学会

    2019年4月 - 現在

      詳細を見る

  • 日本透析医学会

    2019年4月 - 現在

      詳細を見る

委員歴

  • 日本腎臓学会   専門医  

    2024年4月 - 現在   

      詳細を見る

  • 日本腎臓リハビリテーション学会 診療ガイドライン作成委員会   SR委員  

    2024年4月 - 現在   

      詳細を見る

  • 日本透析医学会   専門医  

    2024年4月 - 現在   

      詳細を見る

  • 日本内科学会   内科専門医  

    2022年10月 - 現在   

      詳細を見る

 

論文

  • 不全型Behcet病にみられた好中球浸潤を伴う急性尿細管間質性腎炎の一例

    内田 成彦, 田中 景子, 三宅 広将, 久保田 菜月, 森本 志帆, 志田原 健太, 勝山 隆行, 田邊 克幸, 和田 淳

    日本腎臓学会誌   66 ( 6-W )   1119 - 1119   2024年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本腎臓学会  

    researchmap

  • Early transition to avacopan from glucocorticoids applied during induction therapy for microscopic polyangiitis with rapidly progressive glomerulonephritis.

    Hiromasa Miyake, Katsuyuki Tanabe, Shuhei Yamaji, Takashi Kihara

    CEN case reports   2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease characterized by necrotizing inflammation of small blood vessels. Glucocorticoids (GC) in combination with rituximab or cyclophosphamide can reduce AAV-related mortality and rescue renal function. However, several side effects associated with these agents, including GC toxicity, are concerning. Avacopan, an inhibitor of the C5a receptor, is now available for AAV treatment and is expected to mitigate GC toxicity. We present a case of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-positive microscopic polyangiitis (MPA) with rapidly progressive glomerulonephritis treated with an early switch from GC to avacopan in combination with rituximab during induction therapy. Over a 6-month treatment period, clinical remission was achieved and maintained without infection or elevated liver enzyme levels. Efficacy and safety data regarding avacopan for AAV induction therapy remain limited. Therefore, more case reports are required to clarify the role of avacopan in AAV induction and maintenance therapy. Since the MPO-ANCA titer remained elevated despite the clinical remission of AAV in this case, the ANCA titer may not necessarily be a reliable biomarker for predicting AAV relapse when avacopan is applied as an induction therapy for AAV.

    DOI: 10.1007/s13730-023-00841-3

    PubMed

    researchmap

  • Genetic Deletion of Vasohibin-2 Exacerbates Ischemia-Reperfusion-Induced Acute Kidney Injury. 国際誌

    Hiromasa Miyake, Katsuyuki Tanabe, Satoshi Tanimura, Yuri Nakashima, Tomoyo Morioka, Kana Masuda, Hitoshi Sugiyama, Yasufumi Sato, Jun Wada

    International journal of molecular sciences   21 ( 12 )   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Acute kidney injury (AKI) has been increasingly recognized as a risk factor for transition to chronic kidney disease. Recent evidence suggests that endothelial damage in peritubular capillaries can accelerate the progression of renal injury. Vasohibin-2 (VASH2) is a novel proangiogenic factor that promotes tumor angiogenesis. However, the pathophysiological roles of VASH2 in kidney diseases remain unknown. In the present study, we examined the effects of VASH2 deficiency on the progression of ischemia-reperfusion (I/R) injury-induced AKI. I/R injury was induced by bilaterally clamping renal pedicles for 25 min in male wild-type (WT) and Vash2 homozygous knockout mice. Twenty-four hours later, I/R injury-induced renal dysfunction and tubular damage were more severe in VASH2-deficient mice than in WT mice, with more prominent neutrophil infiltration and peritubular capillary loss. After induction of I/R injury, VASH2 expression was markedly increased in injured renal tubules. These results suggest that VASH2 expression in renal tubular epithelial cells might be essential for alleviating I/R injury-induced AKI, probably through protecting peritubular capillaries and preventing inflammatory infiltration.

    DOI: 10.3390/ijms21124545

    PubMed

    researchmap

  • Renal tubular injury exacerbated by vasohibin-1 deficiency in a murine cisplatin-induced acute kidney injury model. 国際誌

    Satoshi Tanimura, Katsuyuki Tanabe, Hiromasa Miyake, Kana Masuda, Keigo Tsushida, Tomoyo Morioka, Hitoshi Sugiyama, Yasufumi Sato, Jun Wada

    American journal of physiology. Renal physiology   317 ( 2 )   F264-F274   2019年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Acute kidney injury (AKI) is frequently encountered in clinical practice, particularly secondarily to cardiovascular surgery and administration of nephrotoxic agents, and is increasingly recognized for initiating a transition to chronic kidney disease. Clarifying the pathogenesis of AKI could facilitate the development of novel preventive strategies, because the occurrence of hospital-acquired AKI is often anticipated. Vasohibin-1 (VASH1) was initially identified as an antiangiogenic factor derived from endothelial cells. VASH1 expression in endothelial cells has subsequently been reported to enhance cellular stress tolerance. Considering the importance of maintaining peritubular capillaries in preventing the progression of AKI, the present study aimed to examine whether VASH1 deletion is involved in the pathogenesis of cisplatin-induced AKI. For this, we injected male C57BL/6J wild-type (WT) and VASH1 heterozygous knockout (VASH1+/-) mice intraperitoneally with either 20 mg/kg cisplatin or vehicle solution. Seventy-two hours after cisplatin injection, increased serum creatinine concentrations and renal tubular injury accompanied by apoptosis and oxidative stress were more prominent in VASH1+/- mice than in WT mice. Cisplatin-induced peritubular capillary loss was also accelerated by VASH1 deficiency. Moreover, the increased expression of ICAM-1 in the peritubular capillaries of cisplatin-treated VASH1+/- mice was associated with a more marked infiltration of macrophages into the kidney. Taken together, VASH1 expression could have protective effects on cisplatin-induced AKI probably by maintaining the number and function of peritubular capillaries.

    DOI: 10.1152/ajprenal.00045.2019

    PubMed

    researchmap

  • Estrogen-related receptor α is essential for maintaining mitochondrial integrity in cisplatin-induced acute kidney injury. 国際誌

    Keigo Tsushida, Katsuyuki Tanabe, Kana Masuda, Satoshi Tanimura, Hiromasa Miyake, Yuka Arata, Hitoshi Sugiyama, Jun Wada

    Biochemical and biophysical research communications   498 ( 4 )   918 - 924   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Acute kidney injury (AKI) has been associated with not only higher in-hospital mortality but also the subsequent development of chronic kidney disease (CKD). Recent evidence has suggested the involvement of mitochondrial dysfunction and impaired dynamics in the pathogenesis of AKI. Estrogen-related receptor α (ERRα) is an orphan nuclear receptor that acts as a transcription factor to regulate the transcription of genes required for mitochondrial biogenesis and oxidative phosphorylation. In the present study, we examined the effects of ERRα deficiency on the progression of AKI induced by cisplatin. Male C57BL/6 J wild-type and ERRα-/- mice received a single intraperitoneal injection of 20 mg/kg cisplatin. Seventy-two hours after the injection, kidney function and morphology were evaluated. ERRα expression was observed in renal tubules, and cisplatin inhibited its translocation into nuclei. ERRα deficiency exacerbated cisplatin-induced renal dysfunction and tubular injury, as well as oxidative stress and apoptosis. ERRα-/- mice kidneys revealed lower mitochondrial DNA content and swollen mitochondria with reduced cristae. In addition, these mice had lower expression of the mitochondrial fusion protein mitofusin-2. The cisplatin-induced decrease in mitochondrial DNA and altered mitochondrial structure were more severe in ERRα-/- mice. In cultured mouse proximal tubular epithelial cells, the ERRα inverse agonist XCT-790 significantly inhibited mitofusin-2 expression and induced mitochondrial fragmentation. Taken together, our findings suggest the involvement of ERRα in the progression of cisplatin-induced AKI probably through impaired mitochondrial dynamics.

    DOI: 10.1016/j.bbrc.2018.03.080

    PubMed

    researchmap

  • Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model. 国際誌

    Kana Masuda, Katsuyuki Tanabe, Haruyo Ujike, Norikazu Hinamoto, Hiromasa Miyake, Satoshi Tanimura, Hitoshi Sugiyama, Yasufumi Sato, Yohei Maeshima, Jun Wada

    PloS one   13 ( 4 )   e0195779   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Angiogenesis has been implicated in glomerular alterations in the early stage of diabetic nephropathy. We previously reported the renoprotective effects of vasohibin-1 (VASH1), which is a novel angiogenesis inhibitor derived from endothelial cells, on diabetic nephropathy progression. Vasohibin-2 (VASH2) was originally identified as a VASH1 homolog and possesses pro-angiogenic activity in contrast to VASH1. In addition, VASH2 was recently shown to promote epithelial-to-mesenchymal transition via enhanced transforming growth factor (TGF)-β signaling in cancer cells. Herein, we investigated the pathogenic roles of VASH2 in diabetic nephropathy using VAHS2-deficient mice. The type 1 diabetes model was induced by intraperitoneal injections of streptozotocin in VASH2 homozygous knockout (VASH2LacZ/LacZ) or wild-type mice. These mice were euthanized 16 weeks after inducing hyperglycemia. Increased urine albumin excretion and creatinine clearance observed in diabetic wild-type mice were significantly prevented in diabetic VASH2-deficient mice. Accordingly, diabetes-induced increase in glomerular volume and reduction in glomerular slit-diaphragm density were significantly improved in VASH2 knockout mice. Increased glomerular endothelial area was also suppressed in VASH2-deficient mice, in association with inhibition of enhanced vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2), but not VEGF level. Furthermore, glomerular accumulation of mesangial matrix, including type IV collagen, and increased expression of TGF-β were improved in diabetic VASH2 knockout mice compared with diabetic wild-type mice. Based on the immunofluorescence findings, endogenous VASH2 localization in glomeruli was consistent with mesangial cells. Human mesangial cells (HMCs) were cultured under high glucose condition in in vitro experiments. Transfection of VASH2 small interfering RNA (siRNA) into the HMCs resulted in the suppression of type IV collagen production induced by high glucose compared with control siRNA. These results indicate that VASH2 may be involved in diabetes-induced glomerular alterations, particularly impaired filtration barrier and mesangial expansion. Therefore, VASH2 is likely to represent a promising therapeutic target for diabetic nephropathy.

    DOI: 10.1371/journal.pone.0195779

    PubMed

    researchmap

▼全件表示

MISC

  • 外来にて血行再建不能の重症下肢虚血に対し吸着型血液浄化器(レオカーナ)が著効した血液透析患者の1例

    三宅広将, 木原隆司, 山地秀平, 梶原優太, 臺和興, 大峰高広

    中国腎不全研究会誌   31   2023年

     詳細を見る

  • アバコパンにより寛解導入しMPO-ANCA高値のまま寛解に至った多発血管炎性肉芽腫症(GPA)の1例

    三宅広将, 木原隆司, 山地秀平

    日本腎臓学会誌(Web)   65 ( 6-W )   2023年

     詳細を見る

  • 保存期慢性腎不全の二次性副甲状腺機能亢進症に合併したブラウン腫瘍の1例

    三宅広将, 木原隆司, 藤原典子, 古城昭一郎, 研井有紀, 植松周二

    日本透析医学会雑誌   53 ( Supplement 1 )   2020年

     詳細を見る

  • 急性腎障害における血管新生促進因子Vasohibin-2の発現意義についての検討

    三宅広将, 田邊克幸, 益田加奈, 津志田圭吾, 杉山斉, 佐藤靖史, 和田淳

    日本腎臓学会誌   59 ( 3 )   2017年

     詳細を見る